Hologic, Inc.

NasdaqGS:HOLX 株式レポート

時価総額：US$16.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Hologic 過去の業績

過去 基準チェック /06

Hologicの収益は年間平均-29.6%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間13.6% 7.3%割合で 減少しています。 Hologicの自己資本利益率は10.4%であり、純利益率は13.2%です。

主要情報

-29.63%

収益成長率

-26.94%

EPS成長率

Medical Equipment 業界の成長8.90%
収益成長率-7.29%
株主資本利益率10.37%
ネット・マージン13.18%
前回の決算情報27 Dec 2025

最近の業績更新

Recent updates

ナラティブの更新 • Apr 10

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.
ナラティブの更新 • Mar 26

HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes

Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.
ナラティブの更新 • Mar 12

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes

Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.
ナラティブの更新 • Feb 26

HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path

Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.
ナラティブの更新 • Feb 11

HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026

Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.
ナラティブの更新 • Jan 26

HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026

Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.
ナラティブの更新 • Jan 12

HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026

Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.
ナラティブの更新 • Dec 18

HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026

We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.
ナラティブの更新 • Dec 04

HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026

The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.
ナラティブの更新 • Nov 20

HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026

Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.
ナラティブの更新 • Nov 05

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance

Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.
ナラティブの更新 • Oct 22

Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum

Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.
ナラティブの更新 • Sep 28

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.
分析記事 • Sep 13

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
ナラティブの更新 • Sep 05

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.
分析記事 • Aug 04

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...
分析記事 • Jul 19

Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...
分析記事 • Jul 01

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...
分析記事 • Jun 13

Is Hologic (NASDAQ:HOLX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • May 06

Hologic: Soft Performance, But Cheap Enough

Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking Alpha
Seeking Alpha • Jan 17

Hologic: Reasonably, But Not Compellingly Valued

Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions.  Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking Alpha

収支内訳

Hologic の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:HOLX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
27 Dec 254,127544995248
27 Sep 254,101566994248
28 Jun 254,0395571,056251
29 Mar 254,0275571,045253
28 Dec 244,0397441,016266
28 Sep 244,030790995273
29 Jun 243,988702985278
30 Mar 243,961467985287
30 Dec 233,969515984286
30 Sep 234,030456988294
01 Jul 234,0384841,012297
01 Apr 234,0577531,016290
31 Dec 224,4669901,045285
24 Sep 224,8631,3021,038283
25 Jun 225,2261,5121,076284
26 Mar 225,3921,5521,092288
25 Dec 215,4941,7161,040290
25 Sep 215,6321,872994276
26 Jun 215,6632,038921257
27 Mar 215,3171,907870243
26 Dec 204,5361,384827221
26 Sep 203,7761,115840223
27 Jun 203,295497845226
28 Mar 203,325453859232
28 Dec 193,38784895240
28 Sep 193,367-204897232
29 Jun 193,315-30878225
30 Mar 193,287-11882218
29 Dec 183,258-419883217
29 Sep 183,218-111915219
30 Jun 183,207-79866227
31 Mar 183,189-132853235
30 Dec 173,1161,076838233
30 Sep 173,059756819233
01 Jul 172,983765764235
01 Apr 172,894790721231
31 Dec 162,872332686235
24 Sep 162,833331676232
25 Jun 162,809264671223
26 Mar 162,785208667221
26 Dec 152,747187647215
26 Sep 152,705132624215
27 Jun 152,641135610213

質の高い収益: HOLXには$343.6M } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が27th December, 2025に影響を及ぼしています。

利益率の向上: HOLXの現在の純利益率 (13.2%)は、昨年(18.4%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: HOLXの収益は過去 5 年間で年間29.6%減少しました。

成長の加速: HOLXは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: HOLXは過去 1 年間で収益成長率がマイナス ( -27% ) となったため、 Medical Equipment業界平均 ( 14.8% ) と比較することが困難です。

株主資本利益率

高いROE: HOLXの 自己資本利益率 ( 10.4% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/04/06 21:59
終値2026/04/06 00:00
収益2025/12/27
年間収益2025/09/27

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Hologic, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25

アナリスト機関
David ToungArgus Research Company
Charles ButlerBarclays
Charley JonesBarrington Research Associates, Inc.